TB-500
Synthetic fragment of Thymosin Beta-4
Quick Answer
A synthetic peptide based on a fragment of Thymosin Beta-4, a protein naturally involved in cell structure and movement (actin regulation), studied mainly in the context of tissue repair.
Why People Are Interested
Frequently discussed alongside BPC-157 in recovery and sports contexts, largely on shared "peptide recovery stack" community interest rather than its own independent human evidence base.
What People Hope It May Do
Faster tissue and wound healing, and general recovery support, echoing the parent protein's known biology — human evidence to support these specific hopes doesn't yet exist at scale. (Commonly discussed or proposed — not an established, evidence-backed outcome unless separately stated in Human Evidence above.)
Potential / Research Areas
Tissue and wound repair in animal models
Cardiac tissue research (animal models)
Sports-recovery contexts, driven largely by anecdotal/community interest rather than a deep human clinical evidence base
How It May Work
Proposed to promote cell migration and blood vessel formation relevant to wound/tissue healing, based primarily on the parent protein's known biology and animal-model research on the fragment itself.
What Human Research Shows
Very limited. No substantial base of large controlled human clinical trials exists in the public literature.
What Preclinical Research Shows
The primary evidence base — rodent and other animal-model studies of tissue repair and wound healing.
Six independent readings, not one score. This reflects the volume and stage of research and discussion — it is not a rating of safety or effectiveness.
"Real-World Interest" and "Research Momentum" reflect the volume of public discussion and research activity Element Health Labs has observed — an editorial judgment, not a measured statistic, and not a claim about clinical significance. Anecdotal popularity is not evidence of effectiveness.
What People Report
What Experts Are Saying
Curated commentary specific to TB-500 is planned as the Expert & Creator Library grows. Being listed there does not imply an expert's endorsement of Element Health Labs.
Clinical Trials
For the current, authoritative list of registered trials involving TB-500, search ClinicalTrials.gov directly — trial status changes frequently, and that registry is the source of truth, not a static summary on this page.
Potential Risks & Side Effects
No adequate human safety data exists at the scale needed to characterize a real safety profile. This absence of data is itself the key safety-relevant fact.
Regulatory Status
Not FDA-approved for any human use. Frequently sold as a "research chemical," which does not make it lawful for human consumption. It is also a prohibited substance under World Anti-Doping Agency (WADA) rules — prohibited-substance lists are updated periodically, so current status should always be checked directly with WADA.
Recent development (2026-08-17): On July 23, 2026, the FDA's Pharmacy Compounding Advisory Committee voted 8-6 (1 abstention) to recommend adding TB-500 to the FDA's 503A Bulks List, which would let compounding pharmacies legally use it. This is a nonbinding advisory recommendation only — the FDA has not added TB-500 to that list, nothing about its legal status has actually changed, and it remains not FDA-approved. The FDA must still decide whether to proceed through formal notice-and-comment rulemaking. Worth noting for context: the agency's own scientists reportedly opposed the recommendation, and a majority of the panelists who voted yes reportedly have ties to the peptide industry. Full sourcing in This Week in Peptides.
What We Still Don't Know
Whether the animal-model and parent-protein biology translates to any measurable effect in humans, and what a safe or effective human dose — if any — would even look like.
Limitations of Evidence
Almost entirely animal-model or anecdotal; no adequate controlled human trials to cite.
Keep Researching
- Search ClinicalTrials.gov for TB-500
- Expert & Creator Library
- This Week in Peptides
- Understanding Your Bloodwork
- Related peptides:
Last reviewed: 2026-08-17 — FDA compounding-list status re-verified (see Recent development above).